Medical University of Lubeck
The pleiotropic effects of erythropoietin warrant more analysis
Published in Cardiovascular Device Liability Week, January 2nd, 2005
"The primary function of the glycoprotein hormone erythropoietin (Epo) is to promote red cell production by inhibiting apoptosis of erythrocytic progenitors in hemopoietic tissues. However, functional Epo receptors (Epo-R) have recently been demonstrated in various nonhemopoietic tissues indicating that Epo is a more pleiotropic viability and growth factor. Herein, in vitro and in vivo effects of Epo in the brain and the cardiovascular system are reviewed," scientists in Germany report.
"In addition, the therapeutic impact of Epo in oncology is considered, including the question of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- American Heart Association
AHA QI program receives prevention award - Bulgarian Academy of Sciences
Acute cobalt poisoning in vivo depresses Ca-sensitive K currents - Inst. fur Allgemeine & Spezielle Zoologie, Giessen
Action of 5-HT agonists on autonomously contractile compartments was studied - International Medical Center of Japan
ACE1 polymorphism may influence progression of pneumonia in SARS - Stem Cell Research
Creating $3 billion stem cell agency no small feat - Addenbrooke's Hospital, Cambridge
Increased endothelial cell apoptosis may initiate atherosclerosis - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
